This study is to investigate the effects of osthole on cognitive impairment and neuronal degeneration in hippocampus induced by chronic cerebral hypoperfusion in rats, as well as the potential mechanism. Permanent occlusion of bilateral common carotid arteries (2VO) induced severe cognitive deficits tested by the water maze task, along with oxidative stress and neuronal loss in hippocampus. Oral administration of osthole for 3 weeks markedly attenuated cognitive deficits and neuronal damage. Biochemical experiments revealed that osthole decreased the production of malondialdehyde (MDA) and significantly increased the activities of Glutathione Peroxidase (GPx) and Catalase. Western blot analyses indicated that osthole prevented the downregulation of bcl-2 expression and upregulation of bax expression, which resulted in decreasing bax/bcl-2 ratio in hippocampus of 2VO rats. Additionally, osthole effectively alleviated the activation of caspase-3 induced by permanent occlusion of bilateral common carotid arteries. The observed results in present study suggest that osthole exhibits therapeutic potential for vascular dementia, which is most likely related, at least in part, to its antioxidation and anti-apoptotic actions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejphar.2010.03.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sex and APOE genotype modulate neuropsychological profile and depression in temporal lobe epilepsy.
Front Neurosci
January 2025
Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), Cosenza, Italy.
Introduction: Temporal lobe epilepsy is the most common form of focal epilepsy, often associated with cognitive impairments, particularly in memory functions, and depression. Sex and APOE ε4 genotype play a crucial role in modulating cognitive outcomes and depression in various neurological conditions like Alzheimer's disease. However, the combined effects of APOE genotype and sex on cognitive performance and depression in temporal lobe epilepsy have not been previously investigated.
View Article and Find Full Text PDFSerum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting.
Alzheimers Dement (Amst)
January 2025
Neurochemistry Laboratory Department of Laboratory Medicine Amsterdam UMC Amsterdam The Netherlands.
Introduction: Blood-based glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and phosphorylated tau (pTau) have shown promising prognostic potential in Alzheimer's disease (AD), but their applicability in clinical settings where comorbidities are prevalent remains uncertain.
Methods: Simoa assays quantified GFAP, NfL, and pTau181 in retrospectively retrieved prediagnostic serum samples from 102 AD patients and 21 non-AD controls.
Results: Higher serum GFAP levels predicted earlier clinical presentation and faster subsequent Mini-Mental State Examination decline in AD patients.
Enhanced computerized cognitive remediation therapy improved cognitive function, negative symptoms, and GDNF in male long-term inpatients with schizophrenia.
Front Psychiatry
January 2025
Laboratory of Biological Psychiatry, Nantong Mental Health Center, Nantong Brain Hospital & Affiliated Mental Health Center of Nantong University, Nantong, China.
Objective: Negative and cognitive symptoms present significant challenges in patients with schizophrenia, and cognitive remediation is a promising approach to alleviate these symptoms. This study aimed to explore the efficacy of computerized cognitive remediation therapy (CCRT) on psychiatric symptoms, cognitive deficits, and serum levels of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in patients with schizophrenia.
Materials And Methods: Forty male long-term institutionalized inpatients with schizophrenia were assigned to either a CCRT group (n = 20) or a control group (n = 20).
Changes in Neuropsychiatric Symptoms Among COVID-19-Convalescent Patients During Hospitalization at a Tertiary Care Center.
J Neuropsychiatry Clin Neurosci
January 2025
Department of Clinical Research, National Institute of Psychiatry Ramón de la Fuente Muñiz, Mexico City (Coronel Manzo, Flores Ramos); Departments of Neurology (Amscheridam Herrera) and Internal Medicine (Zapata Arenas), General Hospital of Mexico, Mexico City; Third Medical Department and University Cancer Center, Johannes Gutenberg University, Mainz, Germany (de Jesús Naveja); Department of Psychiatry, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City (Castillejos); Faculty of Medicine, Psychiatry, and Mental Health, National Autonomous University of Mexico, Mexico City (López Sepúlveda).
Objective: The investigators compared neuropsychiatric symptoms among COVID-19 patients at hospital admission and at discharge.
Methods: Clinical data on neuropsychiatric syndromes were prospectively collected from 103 COVID-19 patients at admission and immediately before discharge. Clinical evaluations and serum biomarkers were analyzed to assess their relationship with neuropsychiatric symptoms and patient survival.
Synaptic and synchronic impairments in subcortical brain regions associated with early non-cognitive dysfunction in Alzheimer's disease.
Neural Regen Res
January 2025
Laboratorio de Neurofisiología, Departamento de Fisiología, Universidad de Concepción, Concepción, Chile.
For many decades, Alzheimer's disease research has primarily focused on impairments within cortical and hippocampal regions, which are thought to be related to cognitive dysfunctions such as memory and language deficits. The exact cause of Alzheimer's disease is still under debate, making it challenging to establish an effective therapy or early diagnosis. It is widely accepted that the accumulation of amyloid-beta peptide in the brain parenchyma leads to synaptic dysfunction, a critical step in Alzheimer's disease development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!